BioDelivery Sciences (BDSI) announces that it reached an agreement with the FDA concerning the...

|About: BioDelivery Sciences Inte... (BDSI)|By:, SA News Editor

BioDelivery Sciences (BDSI) announces that it reached an agreement with the FDA concerning the development program for its BEMA Buprenorphine/Naloxone drug. The firm says that it anticipates following a plan which would set it up to file for a NDA for the drug in H1 of 2013.